| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | -0.065 | 0.04 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.3 | 0.04 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.04 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.069 | 0.04 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | -0.06 | 0.05 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.11 | 0.05 |
| mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.073 | 0.05 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.1 | 0.05 |
| mRNA | vorinostat:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.067 | 0.05 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.05 |